Apr 1 |
Missed the "Magnificent Seven"? Try Buying These 3 Forever Stocks Instead
|
Apr 1 |
Vertex moves kidney disease drug into late-stage testing
|
Apr 1 |
Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease
|
Apr 1 |
Meet The "Magnificent Seven" of Healthcare Stocks
|
Mar 31 |
1 Top Growth Stock to Buy and Hold Forever
|
Mar 31 |
2 Rock-Solid Growth Stocks to Buy Right Now and Hold for at Least 5 Years
|
Mar 30 |
3 Unstoppable Stocks to Buy Hand Over Fist in April
|
Mar 28 |
Crispr Stock, A Cathie Wood Holding, Dives For The Fifth Straight Week — Here's Why
|
Mar 26 |
3 Biotech Stocks to Buy for the Next Bull Run: March 2024
|
Mar 25 |
Vertex Pharmaceuticals (VRTX) Rises As Market Takes a Dip: Key Facts
|